薯蓣皂苷抑制ERK/p38MAPK信号通路减轻过敏性哮喘小鼠炎症反应

目的探讨薯蓣皂苷对过敏性哮喘小鼠炎症反应的影响及对ERK/p38MAPK信号通路的调控作用。方法 SPF级BALB/c小鼠40只,随机分为对照组、过敏性哮喘模型组、薯蓣皂苷组与地塞米松组,每组10只。利用卵白蛋白致敏联合雾化激发法建立小鼠过敏性哮喘模型。HE染色观察肺组织炎症细胞浸润情况;ELISA检测小鼠血清中OVA特异性免疫球蛋白和小鼠肺泡灌洗液中炎性因子表达;Western blot检测各组小鼠肺组织MAPK信号通路相关蛋白ERK1/2、p38 MAPK、JNK、p-ERK1/2、p-p38 MAPK及p-JNK蛋白表达。结果薯蓣皂苷降低过敏性小鼠肺组织炎性浸润,降低血清中OVA特异性IgE含量(P0.05),降低BALF中炎性因子IL-4、IL-5及IL-13,促进IFN-的表达水平(P0.05),抑制哮喘小鼠肺组织p-ERK1/2,p-p38 MAPK及p-JNK蛋白的表达水平(P0.05)。结论薯蓣皂苷抑制过敏性哮喘小鼠炎症反应,与MAPK信号通路相关。     

葫芦素E通过抑制MAPKs/NF-κB通路减轻哮喘小鼠气道炎症

目的:探讨葫芦素E对哮喘小鼠气道炎症及MAPKs和NF-κB信号通路的影响。方法:将40只健康小鼠随机分成对照组、模型组、葫芦素E低剂量组、葫芦素E高剂量组和地塞米松组。用卵清蛋白致敏法制备哮喘模型,观察各组支气管肺泡灌洗液(BALF)中炎症细胞分类计数、肺组织炎症细胞浸润以及BALF中白细胞介素4(IL-4)、IL-5、IL-13及干扰素γ(IFN-γ)含量的变化;测定肺组织中磷酸化JNK(p-JNK)、磷酸化ERK1/2(p-ERK1/2)、磷酸化p38 MAPK(p-p38 MAPK)和磷酸化NF-κB p65(p-p65)的含量。结果:与正常组比,模型组BALF中炎症细胞数量明显增加,并且MAPKs和NF-κB信号通路相关蛋白活性显著增强。我们发现高剂量葫芦素E可减轻哮喘小鼠气道炎症反应,并明显抑制MAPKs和NF-κB信号通路相关蛋白活性。病理组织学结果显示,模型组小鼠肺组织内有杯状细胞及支气管黏膜上皮细胞增生,肺泡内有炎症细胞浸润,管腔狭窄;各剂量葫芦素E处理组病理改变均较模型组显著减轻。结论:葫芦素E可以减轻哮喘小鼠气道炎症反应,其机制可能与抑制MAPKs和NF-κB信号...     

Apyrase减轻过敏性哮喘小鼠气道炎症及气道重塑

目的探讨apyrase(三磷酸腺苷二磷酸水解酶)对过敏性哮喘小鼠气道炎症及气道重塑的作用。方法采用C57BL/6雌性小鼠建立鸡卵清蛋白(OVA)致敏和激发的过敏性哮喘模型,并给予apyrase处理;以非致敏的同背景雌性小鼠作为对照。于最后1次激发24~48 h,完成小鼠气道高反应性测定、支气管肺泡灌洗及取肺组织。病理学方法评价肺组织气道炎症、杯状细胞及气道重塑,瑞氏吉姆莎染色并计数灌洗液的分类细胞,酶联免疫吸附法测定灌洗液细胞因子,实时定量PCR法测定肺组织转录因子(GATA3)水平。结果 Apyrase减轻哮喘小鼠肺组织嗜酸性粒细胞炎症,降低气道炎性细胞、Th2相关细胞因子及肺组织GATA3核酸水平;减轻气道上皮杯状细胞增生及胶原沉积。结论 Apyrase可减轻小鼠过敏性哮喘的气道炎症及气道重塑。     

牛磺酸对内质网应激介导的过敏性哮喘小鼠气道炎症的影响

目的 探讨牛磺酸（taurine）对过敏性哮喘小鼠气道炎症的影响及其可能的作用机制。方法将24只C57BL/6小鼠随机分为对照组、模型组与牛磺酸组,每组8只,利用卵蛋白（OVA）致敏加激发的方式建立小鼠过敏性哮喘模型。第28 d时处死小鼠,HE染色检测肺组织病理损伤;酶联免疫吸附法（ELISA）检测小鼠血清中OVA特异性免疫球蛋白（OVA-IgE）的表达;ELISA检测小鼠肺泡灌洗液（BALF）中炎症因子白介素（interleukin,IL）-4、IL-5、IL-13及干扰素γ(Interferon,IFN-γ)表达;检测BALF中炎性细胞数量;Western blot检测肺组织中葡糖调节蛋白78(GRP78)、转录因子C/EBP同源蛋白（CHOP）、核因子κ-B(NF-κB)的蛋白表达。结果 牛磺酸可显著改善过敏性哮喘小鼠肺组织病理损伤,降低血清中OVA-IgE含量,降低BALF中炎性因子IL-4、IL-5及IL-13的表达,增加IFN-γ的表达,并显著降低BALF中炎性细胞数量。牛磺酸还能够显著降低过敏性哮喘小鼠肺组织中GRP78、CHOP和NF-κB总蛋白表达。结论 牛磺酸能够抑...     

菠萝蛋白酶诱导小鼠急性过敏性气道炎症的作用研究

探讨菠萝蛋白酶诱导小鼠急性过敏性气道炎症中2型固有淋巴细胞(group 2innate lymphoid cell,ILC2)及相关细胞因子的变化及意义。对未致敏BALB/c雌性小鼠在第1天和第3天给予菠萝蛋白酶滴鼻,ELISA检测12h内小鼠肺组织匀浆上清中IL-33变化,5d后处死小鼠,肺组织切片病理观察,瑞氏染色计数BALF中嗜酸性粒细胞含量,流式检测肺组织中ILC2数量变化,ELISA检测BALF中IL-5、IL-13水平。结果显示,菠萝蛋白酶诱导气道上皮细胞产生IL-33,3h时开始,6h时达高峰;菠萝蛋白酶滴鼻小鼠肺组织切片显示大量炎性细胞浸润和杯状细胞黏液分泌增加,BALF中嗜酸性粒细胞比例增加,IL-5和IL-13含量增加,流式检测肺组织中ILC2数量增多。研究表明,菠萝蛋白酶刺激小鼠气道上皮细胞释放IL-33,引起小鼠肺ILC2活化增殖并分泌大量Th2型细胞因子,引起嗜酸性粒细胞浸润等急性过敏性气道炎症表现,提示ILC2促进早期急性过敏性气道炎症的发生。     

异鼠李素抑制卵清蛋白诱导的哮喘小鼠肺部炎症

目的:探讨异鼠李素对哮喘模型小鼠肺炎的影响并初步分析其机制.方法:将32只BALB/c小鼠随机分为正常对照组、哮喘模型组、异鼠李素低剂量(50 mg/kg)治疗组和异鼠李素高剂量(150 mg/kg)治疗组.利用卵清蛋白(ovalbumin,OVA)构建小鼠哮喘模型.HE染色和PAS染色观察肺组织病理学变化;ELISA...     

朝医麻黄定喘汤对OVA诱导的过敏性哮喘豚鼠模型HMGB1/TLR4/NF-κB信号通路的影响

目的：探讨朝医麻黄定喘汤对过敏性哮喘豚鼠气道炎症的影响,并探讨其作用机制是否与HMGB1/TLR4/NF-κB信号通路有关。方法：选取50只雄性豚鼠随机分为正常对照组、模型组、低剂量（5 g/kg）麻黄定喘汤组、高剂量（20 g/kg）麻黄定喘汤组和地塞米松（0.5 mg/kg）组,每组各10只。除正常对照组外,其余4组均采用卵清蛋白（OVA）腹腔注射致敏和OVA气溶胶雾化激发制备哮喘豚鼠模型。最后一次雾化后观察豚鼠行为学改变;末次激发24 h后处死豚鼠,采集支气管肺泡灌洗液（BALF）,通过Diff-Quik染色进行炎症细胞计数;取肺组织标本,HE、PAS和Masson染色观察肺组织病理学变化;ELISA法检测BALF中IL-4、IL-5和IL-13含量;流式细胞术测定小鼠肺组织中IL-4和IFN-γ水平;Western blot检测肺组织中HMGB1、TLR4、MyD88和NF-κB蛋白表达;免疫组织化学及免疫荧光检测豚鼠肺组织中HMGB1表达。结果：麻黄定喘汤能有效减轻OVA诱导的哮喘豚鼠气道炎症,抑制杯状细胞增生和胶原纤维沉积,减少BALF中IL-4、IL-5和IL-13含量,...     

核因子κB在蛋白激酶C诱导哮喘模型大鼠气道平滑肌细胞增殖中的作用

目的:探讨核因子κB(NF-κB)在蛋白激酶C(PKC)致哮喘模型大鼠气道平滑肌细胞(ASMCs)增殖中的作用。方法:16只Wistar大鼠随机分为哮喘组(8只)和对照组(8只)。应用PKC激动剂PMA和NF-κB抑制剂PDTC干预哮喘组和对照组大鼠ASMCs。采用流式细胞术、MTT法及增殖细胞核抗原(PCNA)免疫荧光技术等方法检测ASMCs增殖;免疫荧光技术及电泳迁移率改变分析(EMSA)检测NF-κB活性。结果:PMA干预哮喘组ASMCs后S期细胞比例、A值、PCNA表达率、NF-κBp65阳性率及结合带的灰度值均显著高于未干预的哮喘组ASMCs(均P<0.05),PDTC预处理后再给予PMA上述指标均低于仅用PMA干预及未干预者(均P<0.05)。仅用PDTC处理的哮喘组ASMCs上述指标均低于未干预的ASMCs(均P<0.05)。结论:NF-κB参与哮喘大鼠ASMCs增殖,在其增殖中存在着PKC-NF-κB信号途径。     

气道上皮细胞上哮喘变应性炎症

气道上皮细胞在哮喘变应性炎症发生中作一种效应细胞，参与介导气道内各种炎性细胞的生存、趋化和活化，它主要通过释放各种细胞因子、炎性介质、趋化因子和粘附分子等对地道变应性炎症发生起重要作用，同时气道上皮细胞又是糖皮质激素治疗哮喘的靶细胞，在哮喘治疗中发挥重要作用。     

miR-155在哮喘患儿痰液的表达及对哮喘小鼠气道炎症的影响

目的探讨miR-155在哮喘患儿及哮喘小鼠中的表达及其对气道炎症的作用。方法应用realtime PCR方法检测哮喘患儿和健康儿童痰液,以及卵清蛋白诱导的哮喘小鼠和正常小鼠肺组织中miR-155的表达;化学合成miR-155模拟物与阴性对照,并分别鼻滴至哮喘小鼠,HE染色验证哮喘小鼠模型的成功建立,免疫荧光方法和western blot方法检测各组小鼠肺组织TNF-α与NF-κB的蛋白表达。结果与对照组相比,哮喘患儿痰液及哮喘小鼠肺组织中miR-155表达显著降低(P0.01);HE染色显示哮喘模型组小鼠炎症细胞浸润明显高于正常对照组,哮喘小鼠模型成功建立。miR-155模拟物滴入后,哮喘小鼠肺组织TNF-α与NF-κB的蛋白表达显著降低(P0.01)。结论 miR-155在支气管哮喘患儿及支气管哮喘小鼠模型中低表达,miR-155模拟物能够抑制哮喘小鼠的气道炎症。     

Pristimerin attenuates ovalbumin-induced allergic airway inflammation in mice

Pristimerin has been shown to possess antiinflammatory activity. However, its potential use for asthma induced by airway inflammation has not yet been studied. First, we established a ovalbumin (OVA)-induced allergic asthma mice model. BALB/c mice were immunized and challenged by OVA. Treatment with pristimerin caused a marked reduction in the levels of OVA-specific IgE, immune cells, and IL-4, IL-5, IL-13 secretion. Histological studies using H&E staining were used to study the alterations in lung tissue. These results were similar to those obtained with dexamethasone treatment. We then investigated which signal transduction mechanisms could be implicated in pristimerin activity by Western blot. The data showed that pristimerin could inhibit MAPKs and NF-κB inflammatory pathways.     

Dihydroartemisinin suppresses ovalbumin-induced airway inflammation in a mouse allergic asthma model

Abstract

Asthma is a complex disease characterized by reversible airway obstruction, airway hyper-responsiveness (AHR) and chronic inflammation of the airways. Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin isolated from the traditional Chinese herb Artemisia annua, has been shown to possess antimalarial and antitumor activities, but whether it can be used in asthma treatment has not been investigated. In this study, we attempted to determine whether DHA regulates inflammatory mediators in the ovalbumin (OVA)-induced mouse asthma model. BALB/c mice were sensitized and challenged by OVA to induce chronic airway inflammation. The intragastrical administration of DHA at 30?mg/kg significantly decreased the number of infiltrating inflammatory cells, T-helper type 2 (Th2) cytokines, OVA-specific immunoglobulin E (IgE) and AHR. Treatment with DHA also attenuated OVA-induced mRNA expression of Muc5ac and chitinase 3-like protein 4 (Ym2) in lung tissues. In addition, lung histopathological studies revealed that DHA inhibited inflammatory cell infiltration and mucus hypersecretion. Then signal transduction studies showed that DHA significantly inhibited extracellular signal-regulated protein kinase (ERK), p38 mitogen-activated protein kinase phosphorylation. DHA also inhibited nuclear factor-κB (NF-κB) activation via the inhibition of phosphorylation of IκBα. These findings provide new insight into the immunopharmacological role of DHA in terms of its effects in a mouse model of asthma.     

IgE regulates airway smooth muscle phenotype: Future perspectives in allergic asthma

The purpose of this commentary is to highlight the emerging role of IgE on airway smooth muscle (ASM) cells function through activation of the high-affinity Fc receptor for IgE. We discuss the potential implications of IgE-mediated ASM sensitization in airway inflammation and remodeling, the hallmark features of allergic asthma.     

Interleukin-18-deficient mice exhibit diminished chronic inflammation and airway remodelling in ovalbumin-induced asthma model

Interleukin (IL)-18, which is produced by activated monocytes/macrophages and airway epithelial cells, is suggested to contribute to the pathophysiology of asthma by modulating airway inflammation. However, the involvement of IL-18 on modulating chronic airway inflammation and airway remodelling, which are characterized in a refractory asthma model exposed to long-term antigen, has not been investigated sufficiently. We examined the role of IL-18 in chronic airway inflammation and airway remodelling by long-term antigen exposure. IL-18-deficient and C57BL/6-wild-type mice were sensitized by ovalbumin (OVA) and were then exposed to aerosolized OVA twice a week for 12 weeks. We assessed airway inflammation by assessing the infiltration of cells into the airspace and lung tissues, and airway remodelling by airway mucus expression, peribronchial fibrosis and smooth muscle thickness. In IL-18-deficient mice, when exposed to OVA, the total cells and neutrophils of the bronchoalveolar lavage fluid (BALF) were diminished, as were the number of infiltrated cells in the lung tissues. IL-18-deficient mice exposed to OVA after 12 weeks showed significantly decreased levels of interferon (IFN)-gamma, IL-13 and transforming growth factor (TGF)-beta1 in the BALF. The airway hyperresponsiveness to acetyl-beta-methacholine chloride was inhibited in IL-18-deficient mice in comparison with wild-type mice. In addition, IL-18-deficient mice exposed to OVA had fewer significant features of airway remodelling. These findings suggest that IL-18 may enhance chronic airway inflammation and airway remodelling through the production of IFN-gamma, IL-13 and TGF-beta1 in the OVA-induced asthma mouse model.     

The effects of nodakenin on airway inflammation,hyper-responsiveness and remodeling in a murine model of allergic asthma

Context: Nodakenin is a major coumarin glucoside in the root of Peucedanum decursivum Maxim, a commonly used traditional Chinese medicine for the treatment of asthma and chronic bronchitis for thousands of years.

Objective: In this work, the anti-asthma potential of nodakenin was studied by investigation of its effect to suppress airway inflammation, hyper-responsiveness and remodeling in a murine model of chronic asthma.

Materials and methods: BALB/c mice sensitized to ovalbumin (OVA) were challenged with aerosolized OVA for 8 weeks, orally administered with nodakenin at doses of 5, 10 and 20?mg/kg before each OVA challenge.

Results: Compared with the model group, nodakenin treatment markedly inhibited airway inflammation, hyper-responsiveness and remodeling, showing improvement in subepithelial fibrosis, smooth muscle hypertrophy, and goblet cell hyperplasia, and decreased levels of interleukin (IL)-4, IL-5, IL-13 and matrix metalloproteinase-2/-9 in bronchoalveolar lavage fluid, and the level of OVA-specific IgE in serum. In addition, the NF-κB DNA-binding activity in lung tissues was also reduced by nodakenin treatment.

Conclusions: These data indicated that nodakenin might mitigate the development of chronic experimental allergic asthma.     

Downregulation of SUMF2 gene in ovalbumin-induced rat model of allergic inflammation

Sulfate-modifying factor 2 (SUMF2), a member of the formylglycine-generating enzyme family, was earlier found to play a role in the regulation of interleukin (IL)-13 expression and secretion in airway smooth muscle cells. IL-13 is a T helper 2 cytokine that plays important roles in the pathogenesis of asthma. However, there is little evidence of the potential role of SUMF2 in the cellular inflammatory responses in asthma. Here, using an ovalbumin-induced asthma rat model, we show that SUMF2 gene expression is significantly decreased in allergic asthma rats. Moreover, several pathological changes were observed in the lung tissue and IL-13 was found to be overexpressed in the ovalbumin-induced asthma model. Additional studies on the lung bronchial epithelial tissues, peripheral blood lymphocytes and bronchoalveolar lavage fluid of the OVA-induced asthma rats showed that SUMF2 mRNA and protein expression were attenuated. However, there was only a little significant correlation was found between SUMF2 and IL-13 expression. These results indicate that SUMF2 may mediate airway inflammation in allergic asthma by modulating the expression of IL-13. More data from in vivo experiments are needed to clearly understand the role of SUMF2 in asthma.     

SP600125 promotes resolution of allergic airway inflammation via TLR9 in an OVA-induced murine acute asthma model

Backgroundc-Jun N-terminal kinase (JNK) relays extracellular stimuli through phosphorylation cascades that lead to various cell responses. In the present study, we aimed to investigate the effect of the JNK inhibitor SP600125 on the resolution of airway inflammation, and the underlying mechanism using a murine acute asthma model.MethodsFemale C57BL/6 mice were sensitized with saline or ovalbumin (OVA) on day 0, and challenged with OVA on day 14–20. Meanwhile, some of the mice were treated with SP600125 (30 mg/kg) intraperitoneally 2 h before each challenge. The airway inflammation was evaluated by counting the numbers of various types of inflammatory cells in bronchoalveolar lavage fluid (BALF), histopathology, cytokines production and mucus secretion in individual mouse. In addition, we analyzed the protein levels of phosphorylated JNK and TLR9 in the lung tissues.ResultsSP600125 markedly reduced the invasion of inflammatory cells into the peribronchial regions, and decreased the numbers of eosinophils, monocytes, neutrophils and lymphocytes in BALF. SP600125 also reduced the level of plasma OVA-specific IgE, lowered the production of pro-inflammatory cytokines in BALF and alleviated mucus secretion. Meanwhile, SP600125 inhibited OVA-induced, increased expression of p-JNK and TLR9 in the lung tissues.ConclusionsCollectively, our data demonstrated that SP600125 promoted resolution of allergic airway inflammation via TLR9 in an OVA-induced murine acute asthma model. The JNK-TLR9 pathway may be a new therapeutic target in the treatment for the allergic asthma.     

二甲双胍抑制慢性哮喘小鼠气道炎症、重塑及新生血管形成

目的:探讨二甲双胍对慢性哮喘气道炎症、重塑及新生血管形成的影响及可能机制。方法:采用卵白蛋白(OVA)致敏并激发制备慢性哮喘小鼠模型,给予二甲双胍干预,与生理盐水对照组和慢性哮喘模型组相比,观察支气管肺泡灌洗液(BALF)细胞计数、外周血免疫球蛋白、气道重塑及磷酸化腺苷酸活化蛋白激酶(pAMPK)蛋白水平的变化。结果:慢性哮喘小鼠BALF细胞总数及嗜酸性粒细胞百分比较对照组升高(P0.01),血清OVA特异性IgE明显升高(P0.01),给药组可降低上述指标(P0.05)。肺组织HE染色可见气道壁炎症细胞浸润、杯状细胞增生、上皮下胶原沉积等病理改变,免疫组化CD31染色观察到气道上皮下新生血管数目和面积增加;二甲双胍部分抑制了上述病理过程。肺组织免疫组化p-AMPK染色观察到其在模型组气道壁的表达较对照组下降(P0.05),给药组升高明显(P0.01)。结论:慢性哮喘中AMPK磷酸化表达水平受抑制。二甲双胍可能通过激活AMPK来抑制慢性哮喘气道炎症、重塑及新生血管的形成。     

Intranasal sirna targeting c-kit reduces airway inflammation in experimental allergic asthma

Allergic asthma is characterized by airway inflammation caused by infiltration and activation of inflammatory cells that produce cytokines. Many studies have revealed that c-kit, a proto-oncogene, and its ligand, stem cell factor (SCF), play an important role in the development of asthmatic inflammation. Intranasal small interference RNA (siRNA) nanoparticles targeting specific viral gene could inhibit airway inflammation. In this study, we assessed whether silencing of c-kit with intranasal small interference RNA could reduce inflammation in allergic asthma. A mouse model of experimental asthma was treated with intranasal administration of anti-c-kit siRNA to inhibit the expression of the c-kit gene. We assessed the inflammatory response in both anti-c-kit siRNA-treated and control mice. Local administration of siRNA effectively inhibited the expression of the c-kit gene and reduced airway mucus secretion and the infiltration of eosinophils in bronchoalveolar lavage fluid. Moreover, c-kit siRNA reduced the production of SCF, interleukin-4 (IL-4), and IL-5, but had no effect on interferon-γ (IFN-γ) generation. These results show that intranasal siRNA nanoparticles targeting c-kit can decrease the inflammatory response in experimental allergic asthma.     

let-7在小鼠哮喘模型气道炎性反应中的作用及机制

目的 观察let-7家族微RNA抑制剂(anti-let-7)对支气管哮喘(简称哮喘)小鼠气道炎性反应的影响,并探讨let-7参与哮喘形成的机制.方法 32只小鼠按随机数字法分为4组(n=8),即正常对照组(A组)、哮喘组(B组)、干预对照组(C组)和干预组(D组).其中B、C和D组用鸡卵蛋白(OVA)免疫,建立哮喘模型,A组以生理盐水替代OVA处理.D组小鼠激发前注射anti-let-7以抑制内源性let-7表达,C组小鼠注射乱序siRNA对照.比较各组小鼠支气管肺泡灌洗液(BALF)的细胞计数,肺组织中let-7e以及BALF中白细胞介素-10(IL-10)含量;体外用anti-let-7转染肺癌细胞A549,并检测细胞中let-7e表达和细胞培养上清中IL-10的含量;荧光素酶报告法检测let-7e是否直接靶向IL-10.结果 与A组相比,B组和C组小鼠BALF中细胞总数和嗜酸粒细胞数显著增加[(20.32±5.33)×109/L和(24.74±6.69)×109/L比(7.12± 1.88)×109/L,(6.45±2.5)×109/L和(7.12±2.66)×109/L比(0.04±0.01)×109/L,均P＜0.01];肺组织中let-7e水平明显升高(分别为3.83倍和3.27倍,均P＜0.01).与C组比较,D组BALF中细胞总数和嗜酸粒细胞数明显减少[(13.85±3.74)× 109/L比(24.74±6.69)×109/L,(2.15±1.13)×109/L比(7.12±2.66)×109/L,均P＜0.05];肺组织中let-7e显著降低[(0.45±0.22)比(3.28±0.45),P＜0.01],同时BALF中IL-10水平明显升高[(4.68±0.85)比(1.70±0.29),P＜0.01].此外,在肺癌细胞A549 中转染anti-let-7,let-7e表达显著下降[(0.22±0.03)比(1.00±0.11),P＜0.01],同时培养上清中IL-10明显上升[(2.58±0.35)比(1.00±0.15),P＜0.01].体外let-7e过表达显著降低IL-10报告载体的荧光素酶活性[(0.59±0.06)比(1.00±0.03),P＜0.01],而对突变的IL-10报告载体没有抑制作用.结论 anti-let-7对哮喘小鼠气道炎性反应具有明显的抑制作用,其作用机制可能与let-7直接靶向并抑制IL-10有关.